Voyageur Pharmaceuticals Appoints Virginia Alling as Independent Director
Calgary, AB — November 7, 2025 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, announced the appointment of Virginia Alling as an independent director, subject to regulatory approval.
This appointment builds on the company’s recent board enhancements, which included the addition of Wall Street veterans Jeffrey J. Kraws and Christopher A. Van Buren. Voyageur believes this strategic move will position the company for accelerated U.S. capital market access and strategic growth.
Alling brings over 30 years of experience in corporate banking, capital markets, and strategic advisory roles. She has worked with both privately held and publicly traded companies. Currently, she is Senior Vice President & Managing Director at PNC Bank in East Brunswick, NJ, where she manages a multi-billion-dollar portfolio of corporate clients in New Jersey and New York. Her responsibilities include M&A, IPOs, ESOPs, leveraged finance, and revenue optimization.
Alling’s expertise includes guiding private equity-backed and multigenerational family-owned businesses through capital structure solutions, succession planning, and risk management. She previously served as Vice President in Corporate Finance & Corporate Banking at JPMorgan Chase (formerly known as Chemical Bank) in New Jersey and Assistant Vice President at Wells Fargo (formerly CoreStates) in Philadelphia.
Alling holds an MBA from the Raymond A. Mason School of Business at the College of William & Mary and is a Registered Investment Adviser (RIA) with FINRA Series 7 & 63 licenses. She also serves as an active board member and nonprofit leader, demonstrating a commitment to technology, healthcare, and philanthropy.
Voyageur’s CEO Brent Willis stated that Alling’s track record in U.S. public offerings, revenue optimization, and cross-border financing complements the recent appointments of Jeffrey Kraws and Christopher Van Buren. He believes Alling’s experience in M&A and capital markets will help the company unlock institutional U.S. investment, streamline its US market entry, and ensure governance as it scales its barium and iodine pipeline for North American healthcare providers.
The appointment of Alling, Kraws, and Van Buren signifies Voyageur’s commitment to assembling a board with Wall Street acumen to facilitate U.S. market expansion. Their collective experience in revenue generation, IPO execution, and regulatory compliance is expected to support Voyageur’s commercialization efforts, including FDA approvals for its barium contrast products and scaling of its Oklahoma iodine operations.
Voyageur Pharmaceuticals Ltd. is focused on developing barium and iodine Active Pharmaceutical Ingredients (API) for high-performance and cost-effective imaging contrast agents. Voyageur aims to vertically integrate the barium and iodine contrast markets. Additionally, Voyageur is pursuing the development of new endo fullerene drugs.
Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. The company believes that its Frances Creek resource will replace the current synthetic products in the pharmaceutical marketplace with higher quality imaging products.
Voyageur’s vision is to become the first vertically integrated company in the radiology contrast media drug market, controlling all primary input costs from raw materials to final production.
For Further Information:
Brent Willis, CEO
Albert Deslauriers, CFO
Brent@vpharma.ca, 403-923-5944
Albert@vpharma.ca
info@vpharma.ca
Source: Voyageur Pharmaceuticals Ltd.
Share this story:
